SUZANE KIOKO ONO

(Fonte: Lattes)
Índice h a partir de 2011
11
Lattes
ResearcherID
Projetos de Pesquisa
Unidades Organizacionais
Departamento de Gastroenterologia, Faculdade de Medicina - Docente
P ICHC, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/07 - Laboratório de Gastroenterologia Clínica e Experimental, Hospital das Clínicas, Faculdade de Medicina

Filtros

Mostrar mais
Limpar filtros

Configurações

Colaboração internacional: China ×

Resultados de Busca

Agora exibindo 1 - 5 de 5
  • conferenceObject
    Worldwide Lack of Early Referral of Patients with Alcoholic Liver Disease: Final Results of the Global Alcoholic Liver Disease Survey (GLADIS)
    (2017) SHAH, Neil D.; VENTURA-COTS, Meritxell; ZHANG, Chaoqun; ZAHIRAGIC, Nerma; YU, Yuanjie; YACOUB, Mohamed A.; WU, Pengbo; WANDERA, Andrew; VOROBIOFF, Julio D.; THURAIRAJAH, Prem H.; TAN, Shiyun; SPRECKIC, Sanjin; SIOW, Way; SCHEURICH, Christoph; SAEZ-ROYUELA, Federico; RODIL, Agustina; REIS, Daniela; ONO, Suzane K.; NABESHIMA, Mariana A.; TEO, Eng Kiong; KARONEY, Mercy J.; FERNANDEZ, Marlen I. Castellanos; FARIAS, Alberto Q.; DOMECH, Caridad Ruenes; COSTA, Pedro Marques Da; ALFADHLI, Ahmad; YANG, Ling; SOME, Fatma; KOCHHAR, Rakesh; KLUWE, Johannes; KIM, Won; ISAKOV, Vasily; HUSIC-SELIMOVIC, Azra; HSIANG, John C.; GEORGE, Jacob; KASSAS, Mohamed El; GURIDI, Zaily Dorta; CARRILHO, Flair J.; BESSONE, Fernando; BADIA, Ester; ALBORAIE, Mohamed; CORTEZ-PINTO, Helena; BATALLER, Ramon
  • conferenceObject
    2-YEAR RESULTS OF TELBIVUDINE (LDT) ROADMAP STUDY VERIFY THE OPTIMAL EFFICACY AND SAFETY RESULTS IN HBEAG POSITIVE CHRONIC HEPATITIS B (CHB) PATIENTS
    (2012) PIRATVISUTH, T.; KOMOLMIT, P.; TANWANDEE, T.; SUKEEPAISARNJAROEN, W.; CHAN, H. L.; PESSOA, M. G.; FASSIO, E.; ONO-NITA, S.; BESSONE, F.; DARUICH, J.; ZEUZEM, S.; CHEINQUER, H.; DONG, Y.; TRYLESINSKI, A.
    Background and Aims: The roadmap concept based on Week 24 HBV DNA levels was prospectively validated with 1year results of Roadmap study (A2410) as previously reported. The 2 year results are reported here. Patients and Methods: All patients were HBeAg positive and started LDT monotherapy from baseline and Tenofovir (LDT) was added to patients with detectable (≥300 copies/ml) HBV DNA at 24w until 104w. Results: 105 patients were enrolled and 100 patients were eligible for modified ITT (mITT) analysis (1 patient with baseline M204I mutation, 2 lost follow-up and 2 didn’t follow roadmap concept). At 24w, 55 patients achieved undetectable HBV DNA and 45 patients with detectable HBV DNA added with TDF (73% of the 45 patients with baseline HBV DNA > 9log10 copies/ml). At 104w, 94% had undetectable HBV DNA, 50%/44% HBeAg loss/seroconversion, 7%/4% HBsAg loss/seroconversion. One patient in LDT mono-treated arm had Virologic Breakthrough (VB) at Week 72 and detected M204I mutation; achieved undetectable HBV DNA 8wks after TDF add-on. One LDT mono-treated patient had one time of HBV DNA increase of 1 log10 above nadir (assessment ongoing). Both patients had baseline HBV DNA > 9log10 copies/ml. In the overall safety population, Serious Adverse Events (SAEs) was reported in 6/105 (5.7%) patients and all unrelated to treatment. No case of myopathy/myositis was reported. Overall GFR (by MDRD formula) improvement was +6.4 and +8.6ml/min/1.73m2 in LDT mono and LDT+TDF group respectively. In patients with abnormal baseline GFR (60–90ml/min/1.73m2), GFR improvement at 2yr was +12.0 and +1.5ml/min/1.73m2 in LDT and LDT+TDF respectively. 50% and 40% of patients with abnormal baseline GFR (60–90ml/min/1.73m2) in LDT and LDT+TDF group respectively shifted to normal (>90ml/min/1.73m2) at 2yr. Only 1 patient in TDF add-on group had once creatinine increase to 232 μmol/L at Week 96, and returned to 91 μmol/L within 4 days. Conclusion: Telbivudine roadmap with tenofovir add-on at 24 weeks in patients with detectable HBVDNA improved GFR in both LDT and LDT+TDF treated patients, as well as favorable efficacy and safety profiles.
  • conferenceObject
    Worldwide lack of early referral of patients with alcoholic liver disease: results of the global alcoholic liver disease survey (GLADIS)
    (2017) SHAH, N. D.; COTS, M. V.; ZHANG, C.; ZAHIRAGIC, N.; YU, Y.; YACOUB, M.; WU, P.; WANDERA, A.; VOROBIOFF, J.; TRAQUINO, E. S. D. S.; THURAIRAJAH, P. H.; TAN, S.; SPRECKIC, S.; SOLER, E. R. A.; SIVAC, N.; SIOW, W.; SCHEURICH, C.; SAEZ-ROYUELA, F.; RODIL, A.; REIS, D.; ONO, S.; NABESHIMA, M.; KIONG, T. E.; KARONEY, M.; GUI, W.; FERNANDEZ, M. C.; FARIAS, A.; DOMECH, C. R.; COSTA, P. M.; BIRYUKOVA, M.; ALFADHLI, A.; YANG, L.; SOME, F.; KOCHHAR, R.; KLUWE, J.; KIM, W.; ISAKOV, V.; HUSIC-SELIMOVIC, A.; HSIANG, J.; GEORGE, J.; KASSAS, M. El; DORTA, Z.; CARRILHO, F. J.; BESSONE, F.; ARANDA, E. B.; ALBORAIE, M.; CORTEZ-PINTO, H.; BATALLER, R.
  • article 83 Citação(ões) na Scopus
    Alcohol-Related Liver Disease Is Rarely Detected at Early Stages Compared With Liver Diseases of Other Etiologies Worldwide
    (2019) SHAH, Neil D.; VENTURA-COTS, Meritxell; ABRALDES, Juan G.; ALBORAIE, Mohamed; ALFADHLI, Ahmad; ARGEMI, Josepmaria; BADIA-ARANDA, Ester; ARUS-SOLER, Enrique; BARRITT, A. Sidney; BESSONE, Fernando; BIRYUKOVA, Marina; CARRILHO, Flair J.; FERNANDEZ, Marlen Castellanos; GUIRIDI, Zaily Dorta; KASSAS, Mohamed El; ENG-KIONG, Teo; FARIAS, Alberto Queiroz; GEORGE, Jacob; GUI, Wenfang; THURAIRAJAH, Prem H.; HSIANG, John Chen; HUSIC-SELIMOVIC, Azra; ISAKOV, Vasily; KARONEY, Mercy; KIM, Won; KLUWE, Johannes; KOCHHAR, Rakesh; DHAKA, Narendra; COSTA, Pedro Marques; PHARM, Mariana A. Nabeshima; ONO, Suzane K.; REIS, Daniela; RODIL, Agustina; DOMECH, Caridad Ruenes; SAEZ-ROYUELA, Federico; SCHEURICH, Christoph; SIOW, Way; SIVAC-BURINA, Nadja; TRAQUINO, Edna Solange dos Santos; SOME, Fatma; SPRECKIC, Sanjin; TAN, Shiyun; VOROBIOFF, Julio; WANDERA, Andrew; WU, Pengbo; YACOUB, Mohamed; YANG, Ling; YU, Yuanjie; ZAHIRAGIC, Nerma; ZHANG, Chaoqun; CORTEZ-PINTO, Helena; BATALLER, Ramon
    BACKGROUND & AIMS: Despite recent advances in treatment of viral hepatitis, liver-related mortality is high, possibly owing to the large burden of advanced alcohol-related liver disease (ALD). We investigated whether patients with ALD are initially seen at later stages of disease development than patients with hepatitis C virus (HCV) infection or other etiologies. METHODS: We performed a cross-sectional study of 3453 consecutive patients with either early or advanced liver disease (1699 patients with early and 1754 with advanced liver disease) seen at 17 tertiary care liver or gastrointestinal units worldwide, from August 2015 through March 2017. We collected anthropometric, etiology, and clinical information, as well as and model for end-stage liver disease scores. We used unconditional logistic regression to estimate the odds ratios for evaluation at late stages of the disease progression. RESULTS: Of the patients analyzed, 81% had 1 etiology of liver disease and 17% had 2 etiologies of liver disease. Of patients seen at early stages for a single etiology, 31% had HCV infection, 21% had hepatitis B virus infection, and 17% had nonalcoholic fatty liver disease, whereas only 3.8% had ALD. In contrast, 29% of patients seen for advanced disease had ALD. Patients with ALD were more likely to be seen at specialized centers, with advanced-stage disease, compared with patients with HCV-associated liver disease (odds ratio, 14.1; 95% CI, 10.5-18.9; P < .001). Of patients with 2 etiologies of liver disease, excess alcohol use was associated with 50% of cases. These patients had significantly more visits to health care providers, with more advanced disease, compared with patients without excess alcohol use. The mean model for end-stage liver disease score for patients with advanced ALD (score, 16) was higher than for patients with advanced liver disease not associated with excess alcohol use (score, 13) (P < .01). CONCLUSIONS: In a cross-sectional analysis of patients with liver disease worldwide, we found that patients with ALD are seen with more advanced-stage disease than patients with HCV-associated liver disease. Of patients with 2 etiologies of liver disease, excess alcohol use was associated with 50% of cases. Early detection and referral programs are needed for patients with ALD worldwide.
  • article 34 Citação(ões) na Scopus
    52-Week Efficacy and Safety of Telbivudine with Conditional Tenofovir Intensification at Week 24 in HBeAg-Positive Chronic Hepatitis B
    (2013) PIRATVISUTH, Teerha; KOMOLMIT, Piyawat; TANWANDEE, Tawesak; SUKEEPAISARNJAROEN, Wattana; CHAN, Henry L. Y.; PESSOA, Mario G.; FASSIO, Eduardo; ONO, Suzane K.; BESSONE, Fernando; DARUICH, Jorge; ZEUZEM, Stefan; CHEINQUER, Hugo; PATHAN, Rashidkhan; DONG, Yuhong; TRYLESINSKI, Aldo
    Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response. The efficacy and safety of this approach applied to telbivudine treatment has not been investigated. Methods: A multinational, phase IV, single-arm open-label study (ClinicalTrials.gov ID NCT00651209) was undertaken in HBeAg-positive, nucleoside-naive adult patients with chronic hepatitis B. Patients received telbivudine (600 mg once-daily) for 24 weeks, after which those with undetectable serum HBV DNA (<300 copies/mL) continued to receive telbivudine alone while those with detectable DNA received telbivudine plus tenofovir (300 mg once-daily). Outcomes were assessed at Week 52. Results: 105 patients commenced telbivudine monotherapy, of whom 100 were included in the efficacy analysis. Fifty-five (55%) had undetectable HBV DNA at Week 24 and continued telbivudine monotherapy; 45 (45%) received tenofovir intensification. At Week 52, the overall proportion of undetectable HBV DNA was 93% (93/100) by last-observation-carried-forward analysis (100% monotherapy group, 84% intensification group) and no virologic breakthroughs had occurred. ALT normalization occurred in 77% (87% monotherapy, 64% intensification), HBeAg clearance in 43% (65% monotherapy, 16% intensification), and HBeAg seroconversion in 39% (62% monotherapy, 11% intensification). Six patients had HBsAg clearance. Myalgia was more common in the monotherapy group (19% versus 7%). No decrease in the mean glomerular filtration rate occurred in either treatment group at Week 52. Conclusions: Telbivudine therapy with tenofovir intensification at Week 24, where indicated by the Roadmap strategy, appears effective and well tolerated for the treatment of chronic hepatitis B.